236 related articles for article (PubMed ID: 29495895)
1. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.
Kauppi K; Rosenthal SB; Lo MT; Sanyal N; Jiang M; Abagyan R; McEvoy LK; Andreassen OA; Chen CH
Am J Psychiatry; 2018 Jul; 175(7):674-682. PubMed ID: 29495895
[TBL] [Abstract][Full Text] [Related]
2. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.
Ruderfer DM; Charney AW; Readhead B; Kidd BA; Kähler AK; Kenny PJ; Keiser MJ; Moran JL; Hultman CM; Scott SA; Sullivan PF; Purcell SM; Dudley JT; Sklar P
Lancet Psychiatry; 2016 Apr; 3(4):350-7. PubMed ID: 26915512
[TBL] [Abstract][Full Text] [Related]
3. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach.
Gaspar HA; Breen G
Sci Rep; 2017 Sep; 7(1):12460. PubMed ID: 28963561
[TBL] [Abstract][Full Text] [Related]
4. Interactome overlap between schizophrenia and cognition.
Koch E; Rosenthal B; Lundquist A; Chen CH; Kauppi K
Schizophr Res; 2020 Aug; 222():167-174. PubMed ID: 32546371
[TBL] [Abstract][Full Text] [Related]
5. Identification and prioritization of gene sets associated with schizophrenia risk by co-expression network analysis in human brain.
Radulescu E; Jaffe AE; Straub RE; Chen Q; Shin JH; Hyde TM; Kleinman JE; Weinberger DR
Mol Psychiatry; 2020 Apr; 25(4):791-804. PubMed ID: 30478419
[TBL] [Abstract][Full Text] [Related]
6. Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.
Putnam DK; Sun J; Zhao Z
AMIA Annu Symp Proc; 2011; 2011():1127-33. PubMed ID: 22195173
[TBL] [Abstract][Full Text] [Related]
7. Identification of relevant hub genes for early intervention at gene coexpression modules with altered predicted expression in schizophrenia.
Rodriguez-López J; Arrojo M; Paz E; Páramo M; Costas J
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Mar; 98():109815. PubMed ID: 31715283
[TBL] [Abstract][Full Text] [Related]
8. Network-based drug repurposing for schizophrenia.
Truong TTT; Liu ZSJ; Panizzutti B; Kim JH; Dean OM; Berk M; Walder K
Neuropsychopharmacology; 2024 May; 49(6):983-992. PubMed ID: 38321095
[TBL] [Abstract][Full Text] [Related]
9. Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes.
Li J; Yoshikawa A; Brennan MD; Ramsey TL; Meltzer HY
Schizophr Res; 2018 Feb; 192():194-204. PubMed ID: 28431800
[TBL] [Abstract][Full Text] [Related]
10. Association between psychiatric hospitalizations of patients with schizophrenia and polygenic risk scores based on genes with altered expression by antipsychotics.
Facal F; Arrojo M; Paz E; Páramo M; Costas J
Acta Psychiatr Scand; 2022 Aug; 146(2):139-150. PubMed ID: 35582973
[TBL] [Abstract][Full Text] [Related]
11. Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery.
Collier DA; Eastwood BJ; Malki K; Mokrab Y
Ann N Y Acad Sci; 2016 Feb; 1366(1):61-75. PubMed ID: 27111133
[TBL] [Abstract][Full Text] [Related]
12. Risk Genes in Schizophrenia and Their Importance in Choosing the Appropriate Antipsychotic Treatment.
Werner FM; Coveñas R
Curr Pharm Des; 2021 Oct; 27(30):3281-3292. PubMed ID: 33588721
[TBL] [Abstract][Full Text] [Related]
13. Network-assisted investigation of antipsychotic drugs and their targets.
Sun J; Xu H; Zhao Z
Chem Biodivers; 2012 May; 9(5):900-10. PubMed ID: 22589091
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.
Maciukiewicz M; Tiwari AK; Zai CC; Gorbovskaya I; Laughlin CP; Nurmi EL; Liebermann JA; Meltzer HY; Kennedy JL; Müller DJ
Schizophr Res; 2019 Oct; 212():204-212. PubMed ID: 31447353
[TBL] [Abstract][Full Text] [Related]
16. The search for novel antipsychotics: pharmacological and molecular targets.
Sanger DJ
Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
[TBL] [Abstract][Full Text] [Related]
17. Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia.
Wimberley T; Gasse C; Meier SM; Agerbo E; MacCabe JH; Horsdal HT
Schizophr Bull; 2017 Sep; 43(5):1064-1069. PubMed ID: 28184875
[TBL] [Abstract][Full Text] [Related]
18. Indicated association between polygenic risk score and treatment-resistance in a naturalistic sample of patients with schizophrenia spectrum disorders.
Werner MCF; Wirgenes KV; Haram M; Bettella F; Lunding SH; Rødevand L; Hjell G; Agartz I; Djurovic S; Melle I; Andreassen OA; Steen NE
Schizophr Res; 2020 Apr; 218():55-62. PubMed ID: 32171635
[TBL] [Abstract][Full Text] [Related]
19. A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes.
de Jong S; Boks MP; Fuller TF; Strengman E; Janson E; de Kovel CG; Ori AP; Vi N; Mulder F; Blom JD; Glenthøj B; Schubart CD; Cahn W; Kahn RS; Horvath S; Ophoff RA
PLoS One; 2012; 7(6):e39498. PubMed ID: 22761806
[TBL] [Abstract][Full Text] [Related]
20. A computational network analysis based on targets of antipsychotic agents.
Gao L; Feng S; Liu ZY; Wang JQ; Qi KK; Wang K
Schizophr Res; 2018 Mar; 193():154-160. PubMed ID: 28755876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
